Commitments and Contingencies	3 Months Ended
Mar. 31, 2020
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	9.Commitments and Contingencies Contract Obligations As of March 31, 2020, the Company had outstanding total non-cancelable contract obligations of $23.5 million, including $11.9 million for manufacture and supply of roxadustat, $11.0 million for future milestone payments for research and pre-clinical stage development programs, and $0.6 million for other purchases. The Company expects to fulfill our commitments under these agreements in the normal course of business, and as such, no liability has been recorded. Legal Proceedings The Company is a party to various legal actions that arose in the ordinary course of its business. The Company did not have any material accruals for any currently active legal action in its consolidated balance sheets as of March 31, 2020, as it could not predict the ultimate outcome of these matters, or reasonably estimate the potential exposure. Indemnification Agreements The Company enters into standard indemnification arrangements in the ordinary course of business, including for example, service, manufacturing and collaboration agreements. Pursuant to these arrangements, the Company indemnifies, holds harmless, and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, including in connection with intellectual property infringement claims by any third party with respect to its technology. The term of these indemnification agreements is generally perpetual any time after the execution of the agreement. The Company has entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers to the extent permissible under applicable law. The maximum potential amount of future payments the Company could be required to make under these arrangements is not determinable. The Company has never incurred costs to defend lawsuits or settle claims related to these indemnification agreements. As a result, the Company believes the estimated fair value of these arrangements is minimal.

Commitments and Contingencies

3 Months Ended

Mar. 31, 2020

Commitments And Contingencies Disclosure [Abstract]

9.Commitments and Contingencies

Contract Obligations

As of March 31, 2020, the Company had outstanding total non-cancelable contract obligations of $23.5 million, including $11.9 million for manufacture and supply of roxadustat, $11.0 million for future milestone payments for research and pre-clinical stage development programs, and $0.6 million for other purchases. The Company expects to fulfill our commitments under these agreements in the normal course of business, and as such, no liability has been recorded.

Legal Proceedings

The Company is a party to various legal actions that arose in the ordinary course of its business. The Company did not have any material accruals for any currently active legal action in its consolidated balance sheets as of March 31, 2020, as it could not predict the ultimate outcome of these matters, or reasonably estimate the potential exposure.

Indemnification Agreements

The Company enters into standard indemnification arrangements in the ordinary course of business, including for example, service, manufacturing and collaboration agreements. Pursuant to these arrangements, the Company indemnifies, holds harmless, and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, including in connection with intellectual property infringement claims by any third party with respect to its technology. The term of these indemnification agreements is generally perpetual any time after the execution of the agreement. The Company has entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers to the extent permissible under applicable law. The maximum potential amount of future payments the Company could be required to make under these arrangements is not determinable. The Company has never incurred costs to defend lawsuits or settle claims related to these indemnification agreements. As a result, the Company believes the estimated fair value of these arrangements is minimal.